Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verapamil versus Kenacort-based intralesional injections for hypertrophic and keloid scars
NL-OMON43777Phase 2Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Hypertrophic Scar (HS) and keloid comparing Verapamil, Verapamil + Kenacort and Kenacort (3 arms). Primary endpoint: Change in scar volume. Started Feb 2016; status: active, not recruiting.
02
Drugs
verapamiltriamcinolone acetonide
03
Conditions
Hypertrophic Scar (HS)keloid
Beyond the preview
Go deeper on NL-OMON43777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43777.